Legislators across the USA continue to debate the safety of kratom, an opioid mimicking plant that has been noted as a "drug of issue" by the U.S. Food and Drug Administration. Kratom is sold non-prescription in specialized stores and online.
Compound abuse conditions are a major health issue in the UNITED STATE and also a growing variety of people suffering from these conditions are self-medicating with kratom to help break a cycle of reliance. After tobacco, the most typically abused substance in the UNITED STATE is alcohol with virtually 15 million people detected with an alcohol usage disorder.
A Purdue University team released a paper in the Nov. 8 version of the British Journal of Pharmacology analyzing the impacts of kratom and also the possible influence on individuals with alcohol use condition. The price to people and society from alcohol usage is estimated at greater than $250 billion yearly.
One huge obstacle is that alcohol usage disorder is not appropriately treated with currently readily available medications; as a matter of fact less than 10% of individuals get therapy. Few broadly effective medication treatments exist to treat alcohol abuse condition, so finding brand-new and better treatments is of crucial value to help people manage their condition."
Richard van Rijn, associate professor in Purdue's University, who led the study team
The Purdue researchers, in cooperation with scientists at Memorial Sloan-Kettering as well as Washington University, studied the prospective impacts of kratom as well as its effects on the body and also its potential to decrease alcohol usage.
" Our research shows that kratom may work to self-medicate an alcohol abuse problem but is not completely safe," van Rijn said. "Instead, our research provides added support for various other therapies that would not create the noticeable adverse effects of using kratom, which might also be habit forming."
The Purdue team previously focused on a G protein-coupled receptor, called the delta opioid receptor, which is a novel drug target that is various from the receptor in the body that binds prescription opioids. They established medications that bind to this new target as well as uniquely turn on a certain healthy protein signalling cascade of this receptor.
Gutridge, A.M., et al. (2019) G protein-biased kratom-alkaloids and synthetic carfentanil-amide opioids as potential treatments for alcohol use disorder. British Journal of Pharmacology. doi.org/10.1111/bph.14913.
You'll be seeing quite a few changes within the Kratom.com brand, including an updated logo, packaging—and much more. We're celebrating 20 years in the industry and felt like it was time to freshen things up a bit. However, one thing that will always remain the same is the quality of our products. We'll always carry and supply the original Maeng Da™ and Bali Premium™—that we introduced to the market in 2001 as well as the service that you've come to expect. This is year come with some surprises that will go hand-in-hand with the new brand - for example, new value oriented savings opportunities for both consumers and our vendor and distributor partners, a NEW local Vendor Locator Map and or course a handful of exciting new products like our new Kratomade™ instant, flavored extracts and the first ever Salt-Based (SB-1™) extracts—two exciting game changers. As always, don't hesitate to reach out to us with any questions!
The Kratom.com Team!
New product alerts, discounts and merch opps